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Gestational trophoblastic disease (GTD) is a group of uncommon con-
ditions associatedwith abnormal pregnancy. Histologically, it includes the
benign partial and complete hydatidiform mole, invasive and metastatic
mole, aswell as themalignant choriocarcinoma, placental site trophoblas-
tic tumor (PSTT), and epithelioid trophoblastic tumor (ETT). Molar preg-
nancies may develop persistent elevated serum human chorionic
gonadotropin (hCG) levels after evacuation (complete mole 15%−20%,
partial mole 0.1%−5% [1–3]), with a chance of progression to choriocarci-
noma that may require treatment. Together with the malignant forms of
GTD these are grouped under gestational trophoblastic neoplasia (GTN).
2. Epidemiology
Molar pregnancy ismore common in some parts of Asia, with report-
ed incidence rates as high as 2 per 1000 pregnancies [4,5] comparedwith
Europe and North American where the incidence is usually reported to
be less than 1 per 1000 pregnancies [6,7]. However, the incidence of
molar pregnancy seems to be decreasing in Asian countries, possibly re-
lated to improvements in the economy and diet as well as a decrease in
birth rates [4].
The incidence of choriocarcinoma is difﬁcult to estimate because of
its rarity and trouble in clinically distinguishing postmolar choriocarci-
noma from invasive mole owing to lack of histologic biopsy material.
Although choriocarcinoma has been reported to affect approximately
1 in 40 000 to 9 in 40 000 pregnancies [3], the incidence rates have
been declining. PSTT and ETT are rarer than choriocarcinoma.
3. Genetics and pathology
3.1. Molar pregnancy
Histologically, complete mole has ﬂorid cistern formation, tropho-
blastic proliferation, and absence of fetal parts. In contrast, suchhttp://dx.doi.org/10.1016/j.ijgo.2015.06.008
0020-7292/© 2015 Published by Elsevier Ireland Ltd. on behalf of International Federation of
(http://creativecommons.org/licenses/by-nc-nd/4.0/).histological features are less marked in partial mole and fetal parts are
present, such as fetal cells [8]. Hydropic spontaneous abortion may
mimic the appearance of partial mole.
Cytogenetics can help to differentiate complete mole from partial
mole and hydropic spontaneous abortion. Typically, complete mole is
diploid and has 46,XX chromosomes with both Xs from paternal origin
whereas partial mole is triploid with maternal and paternal genetic
origin. Hydropic spontaneous abortion normally has 46,XX or XY from
both parents. Immunohistochemical staining of p57Kip2, which is an
imprinted gene, can help to show the presence of maternal genes and
enable complete mole to be excluded [8,9].
Rarely, invasive and metastatic moles can be diagnosed by removal
of the uterus or a metastatic lesion.3.2. Choriocarcinoma
Choriocarcinoma is a malignant tumor with absence of chorionic
villi, abnormal syncytiotrophoblast and cytotrophoblast, necrosis, and
hemorrhage. It may invade the uterus and surrounding organs and it
is common to have distant spread, particularly to the lung, but it may
also involve the liver, spleen, kidneys, bowels, and brain [8].3.3. Placental site trophoblastic tumor
PSTT arises from the mononuclear intermediate trophoblast on the
maternal side of the placental bed invading the myometrium. It has
variable size and appearance, may be tan or yellowish with foci of necro-
sis, and on average is about 5 cm in size. Tumor cells have irregular
nuclear membranes, hyperchromatic nuclei, and dense eosinophilic to
amphophilic cytoplasm. Chorionic villi are absent. Tumor cells are strong-
ly and extensively reactive to human placental lactogen (hPL) but only
focally reactive to hCG. It has to be differentiated from the benign
exaggerated placental site reaction where the Ki67 index is lower [8].Gynecology and Obstetrics. This is an open access article under the CC BY-NC-ND license
Box 2
Tools for investigation of gestational trophoblastic neoplasia.
• Chest X-ray is appropriate to diagnose lung metastases and it is
chest X-ray that is used for counting the number of lung
metastases to evaluate the risk score. Lung CT may be used.
• Liver metastases may be diagnosed by ultrasound or CT
scanning.
• Brain metastases may be diagnosed by MRI or CT scanning.
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ETT is a lesion of chorionic-type intermediate trophoblast. It usually
appears as a discrete, hemorrhagic, solid, and cystic lesion.
It may be found in the fundus, lower uterine segment, or endocervix,
or even the broad ligament. Histologically, islands of intermediate tro-
phoblastic cells are surrounded by extensive necrosis and associated
with a hyaline-like matrix. The tumor is focally immunoreactive to
hPL, hCG, cytokeratin, and inhibin-alpha. It can be differentiated from
PSTT by positive p63 immunostaining. ETT may coexist with choriocar-
cinoma or PSTT [10–12]. Emerging data indicate that atypical placental
site nodules (APSN) can co-exist and/or preceded ETT and PSTT,
suggesting that at least APSN cannot be regarded as benign [13].4. Clinical presentation, investigations, and diagnosis
4.1. Molar pregnancy
The most common presentation of a hydatidiform mole is abnormal
vaginal bleeding in pregnancy.With the advent of ultrasound assessment
of early pregnancy complications, molar pregnancy is usually diagnosed
during the ﬁrst trimester. Hence, the previous classical presentations of
hyperemesis gravidarum, hyperthyroidism, pre-eclampsia, pulmonary
trophoblastic embolization, and uterine size larger than dates are rarely
seen nowadays.
The typical snow storm appearance of complete mole may not be
seen in early ﬁrst trimester complete mole. Absence of fetal parts, cystic
appearance of the placenta, and deformed gestational sac may indicate
early molar pregnancy. Hence, some molar pregnancies are only diag-
nosed on histological examination after dilation and curettage for a
spontaneous abortion.4.2. Gestational trophoblastic neoplasia
PostmolarGTN is usually diagnosedby hCG surveillance. Patients are
generally asymptomatic. At the 2000 FIGO Gynecology Oncology Com-
mittee meeting the deﬁnition of postmolar GTN based on hCG-level
changes, histology, and speciﬁc investigations was agreed upon
(Boxes 1 and 2) [14].4.3. Human chorionic gonadotropin monitoring
Formonitoring of GTN, an hCG assay that can detect all forms of hCG,
such as beta-hCG, core hCG, C-terminal hCG, nicked-free beta, beta core,
and preferably the hyperglycosylated forms, should be used; these are
different from those used for a routine pregnancy test. A persistent
low hCG level should be followed up, after exclusion of false positives
due to heterophile antibodies, as somemay progress to GTNwith rising
hCG level [15,16].Box 1
FIGO criteria for diagnosis of postmolar gestational trophoblastic
neoplasia.
• When the plateau of hCG lasts for four measurements over a
period of 3 weeks or longer; that is, days 1, 7, 14, 21.
• When there is a rise in hCG for three consecutive weekly
measurements over at least a period of 2 weeks or more; days 1,
7, 14.
• When the hCG level remains elevated for 6 months or more.
• If there is a histologic diagnosis of choriocarcinoma.
Abbreviation: hCG, human chorionic gonadotropin.4.4. Gestational trophoblastic neoplasia after non-molar pregnancy
As only about 50% of GTN followsmolar pregnancy, the rest can occur
after a spontaneous abortion, ectopic pregnancy, or a term pregnancy
where no hCG monitoring would be recommended. Therefore, clinical
presentations vary from abnormal vaginal bleeding; bleeding frommeta-
static sites in the abdomen, lung, or brain; pulmonary symptoms; and
neurological signs from spine or brainmetastasis [3]. GTN should be con-
sidered in the differential diagnosis of patients with unusual presenta-




Suction evacuation of molar pregnancy should be carried out by an
experienced gynecologist, especially if the uterus is larger than
16 weeks gravid size and ideally under ultrasound guidance. The risk
of heavy bleeding can be reduced with use of oxytocics given after dila-
tion and the onset of suction curettage. If there is no persistent bleeding,
second evacuation is usually not needed. Hysterectomy is rarely indicat-
ed unless there is a co-existing indication.
Follow-up with hCG monitoring is essential for early diagnosis of
postmolar GTN. Recent data show that GTN rarely occurs after the
hCG has spontaneously returned to normal and hence contraception
for only 6 months rather than 1 year is now recommended [3,17]. Ter-
mination of pregnancy is not indicated if accidental pregnancy occurs
during surveillance after the hCG level has returned to normal. Also,
data now show that it is safe to recommend oral contraceptives [18].
The risk of recurrence is low (0.6%–2%) after one molar pregnancy,
although much increased after consecutive molar pregnancies [19–21].
Mutations in NLRP7 and KHDC3L have been reported in womenwith re-
current molar pregnancy [22–24].
5.2. Co-existing normal pregnancy with mole
Molar pregnancy rarely co-exists with a normal pregnancy. The di-
agnosis is usually made on ultrasound. Although there is a high risk of
spontaneous abortion, about 40% result in live births without signiﬁ-
cantly increasing the risk of GTN [25]. Hence, in the absence of compli-
cations and normal genetic and ultrasound ﬁndings, pregnancy can be
allowed to proceed.Table 1
FIGO staging and classiﬁcation for gestational trophoblastic neoplasia.
FIGO Stage Description
I Gestational trophoblastic tumors strictly conﬁned to the uterine corpus
II Gestational trophoblastic tumors extending to the adnexae or to the
vagina, but limited to the genital structures
III Gestational trophoblastic tumors extending to the lungs, with or without
genital tract involvement
IV All other metastatic sites
Table 2
FIGO/WHO scoring system based on prognostic factors.
FIGO/WHO risk factor scoring with
FIGO staging
0 1 2 4
Age b40 N40 – –
Antecedent pregnancy Mole Abortion Term
Interval from index pregnancy, months b4 4–6 7–12 N12
Pretreatment hCG mIU/mL b103 N103–104 N104–105 N105
Largest tumor size including uterus, cm – 3–4 ≥5 –
Site of metastases including uterus lung Spleen, kidney Gastrointestinal tract Brain, liver
Number of metastases identiﬁed – 1–4 5–8 N8
Previous failed chemotherapy – – Single drug Two or more drugs
Notes: To stage and allot a risk factor score, a patient’s diagnosis is allocated to a Stage as represented by a Romannumeral I, II, III, or IV. This is then separated by a colon from the sum of all
the actual risk factor scores expressed in Arabic numerals e.g. Stage II:4, Stage IV:9. This Stage and score will be allotted for each patient.
Table 3
EMA-CO (etoposide, methotrexate, actinomycin D, cyclophosphamide, vincristine)
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Treatment of GTN is generally by chemotherapy. Thebest regimen to
use depends on stage and classiﬁcation. In the 2000 FIGO staging and
classiﬁcation (Tables 1 and 2), a risk score of 6 and below is classiﬁed
as low risk and above 6 is considered high risk.
5.3.1. Low-risk gestational trophoblastic neoplasia
Patients with low-risk GTN should be treated with one of the single-
agent methotrexate or actinomycin D protocols listed in Box 3. The
Cochrane Review in 2012, including 513 patients in ﬁve randomized
controlled trials, showed that actinomycin D (Act-D) appeared to be su-
perior to methotrexate (MTX) (risk ratio [RR] 0.64; 95% conﬁdence in-
terval, [CI] 0.54−0.76) [26]. Methotrexate was associated with
signiﬁcantly more treatment failure than actinomycin D (RR 3.81; 95%
CI, 1.64−8.86). A further trial is ongoing, comparing not only efﬁcacy,
but toxicity and quality of life of pulsed actinomycin D and multiday
methotrexate regimens [27].
Chemotherapy should be changed to the alternative single agent if
there has been a good response to the ﬁrst agent but the hCG level pla-
teaus above normal during treatment or if toxicity precludes an adequate
dose or frequency of treatment. If there is an inadequate response to the
initial single agent, a signiﬁcant elevation in hCG level, development of
metastasis, or resistance to sequential single-agent chemotherapy,
multi-agent chemotherapy as for high-risk disease should be initiated
[2]. Studies in the UK showed that if the hCG level is less than 100 IU/L
or 300 IU/L, change to single-agent Act-D gives a good response [2,28,
29]; otherwise, multiple agents need to be used.
After the hCG level has returned to normal, consolidation with 2–3
more cycles of chemotherapy will decrease the chance of recurrence.
The overall complete remission rate is close to 100% [2,30].
5.3.2. High-risk gestational trophoblastic neoplasia
Multiple agent chemotherapy regimens are used to treat high-risk
GTN. The most commonly used is EMA-CO (etoposide, methotrexate,Box 3
Single-agent chemotherapy regimens for low-risk gestational tropho-
blastic neoplasia.
• MTX-FA 8-day regimen (50 mg MTX intramuscularly on days
1,3,5,7 with folinic acid 15 mg orally 24 h after MTX on days
2,4,6,8); repeat every 2 weeks.
• MTX 0.4 mg/kg (max. 25 mg) intravenously or intramuscularly
for 5 days every 2 weeks.
• Actinomycin D pulse 1.25 mg/m2 intravenously every 2 weeks.
• Actinomycin D 0.5 mg intravenously for 5 days every 2 weeks
• Others: MTX 30–50 mg/m2 intramuscularly weekly, MTX 300
mg/m2 infusion every 2 weeks, 5-fluorouracil, etoposide.
Abbreviations: MTX-FA, methotrexate−folinic acid.actinomycin D, cyclophosphamide, vincristine) (Table 3), although the
Cochrane Database review [31] failed to conclude what combination
was best. The complete remission rate was approximately 85% and the
ﬁve-year overall survival rate was 75%−90%. However, patients with
liver and/or brain metastasis have poorer outcomes [32–34].5.3.3. Ultra high-risk gestational trophoblastic neoplasia and salvage
therapy
Among the high-risk group as deﬁned by the FIGO staging and clas-
siﬁcation, a subgroup with a score greater than or equal to 12 as well as
patients with liver, brain, or extensive metastases did poorly when
treated with ﬁrst-line multiple agent chemotherapy [35].
For those with massive disease, starting with standard chemothera-
py may cause severe marrow suppression leading to bleeding, septice-
mia, and even multiple organ failure. This may be avoided by starting
with a lower dose and a less intensive regimen, such as etoposide
100 mg/m2 and cisplatin 20 mg/m2 on days 1 and 2, repeated weekly
for 1–3 weeks, before starting the usual chemotherapy regimen [36].
For those patients with liver or brain metastases or a very high-risk
score, EP (etoposide and platinum)/EMAor anothermore intensive che-
motherapy regimen (Table 4), rather than EMA, may yield a better re-
sponse and outcome. Such regimens can also be used in treating
relapse or progressive disease while on ﬁrst-line chemotherapy. For
such high-risk patients, a longer consolidation with four cycles of che-
motherapy should be considered.
In patients with brain metastases, an increase in the methotrexate
infusion to 1 g/m2 will help the drug cross the blood brain barrier and
intrathecal methotrexate 12.5 mg can be given at the time of CO when
EMA-CO is used. Some centers may give whole brain radiotherapy
3000 cGy in 200 cGy daily fractions concurrent with chemotherapy or




Etoposide 100 mg/m2 intravenous infusion over 30 minutes
Actinomycin-D 0.5 mg intravenous bolus
Methotrexate 100 mg/m2 intravenous bolus
200 mg/m2 intravenous infusion over 12 hours
Day 2
Etoposide 100 mg/m2 intravenous infusion over 30 minutes
Actinomycin-D 0.5 mg intravenous bolus
Folinic acid rescue 15 mg intramuscularly or orally every 12 hours for four doses
(starting 24 hours after beginning the methotrexate infusion)
Regimen 2
Day 8
Vincristine 1 mg/m2 intravenous bolus (maximum 2 mg)
Cyclophosphamide 600 mg/m2 intravenous infusion over 30 minutes
The two regimens alternate each week
Table 4
Salvage chemotherapy.
• EP-EMA (etoposide, cisplatin, etoposide, methotrexate and actinomycin-D)
• TP/TE (paclitaxel, cisplatin/paclitaxel, etoposide)
• MBE (methotrexate, bleomycin and etoposide)
• VIP or ICE (etoposide, ifosfamide, and cisplatin or carboplatin)
• BEP (bleomycin, etoposide and cisplatin)
• FA (5-ﬂuorouracil, actinomycin-D)
• FAEV (ﬂoxuridine, actinomycin-D, etoposide and vincristine)
• High-dose chemotherapy with autologous bone marrow or stem cell transplant
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Surgery may have an important role in the management of GTN.
Hysterectomy can be considered in uncontrolled uterine bleeding,
although it can often be avoidedwith the use of uterine artery emboliza-
tion. Laparotomy may be needed to stop bleeding in organs such as the
liver, gastrointestinal tract, kidneys, and spleen. Neurosurgery is needed
if there is bleeding into the brain or increased intracranial pressure. In
patients with an isolated drug-resistant tumor, removal of isolated cra-
nial or pulmonary nodules or hysterectomy can improve survival.
5.5. Role of radiotherapy
Radiotherapy has a limited role in GTN, except in treatment of brain
metastasis, although its efﬁcacy compared with intrathecal methotrex-
ate is controversial [33,37].
5.6. PSTT/ETT
Both PSTT and ETT are less chemosensitive than choriocarcinoma.
Hysterectomy is the primary mode of treatment in most cases. However,
if fertility preservation is desired, especially in a localized lesion, conser-
vative management such as uterine curettage, hysteroscopic resection,
and chemotherapy may be considered. Fertility preservation is not suit-
able in diffuse lesions. EP-EMA is the most commonly used chemothera-
py. Interval fromantecedent pregnancy ofmore than 48months seems to
be the most signiﬁcant adverse prognostic factor.
5.7. Follow-up
After treatment of GTN, frequent monitoring of hCG for at least
12 months with reliable contraception is essential for surveillance
of relapse.
Future fertility, pregnancy, and offspring are not affected, although
psychosocial and sexual counseling may be needed for some patients.
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